Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

A reptile hunter sprang into action last week to remove a 16-foot python that was slithering around a dumpster at a Los Angeles apartment building. Dramatic video shows 24-year-old Joseph Hart — ...

LOS ANGELES (KABC) -- What would you do if you found a 20-foot python in your apartment complex's dumpster? Well, that's exactly what happened Tuesday in Los Angeles. Joseph Hart - who's known as the ...

There will soon be another 256 families living in Beacon, New York thanks to a development deal from the MTA. The Metropolitan Transportation Authority Board has granted approval to Jonathan Rose ...

The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. This was largely due to news from a ...

Friday night, June 6, a North Texas neighborhood in Garland was on edge as a 15-foot reticulated python escaped from his owner and was on the loose slithering through the streets. CBS Texas reports ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...